Skip to main content
BNTC logo

Benitec Biopharma Inc.

BNTCNASDAQHealthcareBiotechnology

$8.11Today:- (-)1Y −45.94%

As of Oct 16, 2026 close

Market cap
$393.88M
P/E (TTM)
-
Forward P/E
-
Dividend yield
-
52-week range
$8.25$16.76
Volume (live)
-
Avg. volume (3M)
178.49K

Benitec Biopharma (BNTC) Financial Ratios

For fiscal 2026 (fiscal year ended Jun 30, 2026), Benitec Biopharma had return on equity of -33.2% (up from -52.5%), debt-to-equity of 0.00 (down from 0.01), a current ratio of 34.00 (down from 54.67) and return on assets of -22.7% (up from -34.4%). A current ratio of 34.00 means current assets exceed current liabilities.

Benitec Biopharma Financial Ratios Analysis

Valuation, profitability, leverage, and liquidity ratios

Scroll to see more
BreakdownFY 2026FY 2025FY 2024FY 2023FY 2022FY 2021
Period endingJun 2026Jun 2025Jun 2024Jun 2023Jun 2022Jun 2021
Valuation Ratios
P/S Ratio---88.98129.85565.78
P/B Ratio2.603.161.3933.043.291.67
Price/Tangible Book2.603.161.3933.043.291.67
Enterprise Value Ratios
EV/Revenue---9.9423.51367.04
Profitability & Returns
Return on Equity (ROE)-33.21%-52.46%-91.68%-1268.61%-159.08%-91.79%
Return on Assets (ROA)-22.67%-34.39%-49.60%-228.53%-81.59%-51.55%
Return on Capital Employed (ROCE)-28.90%-42.70%-47.60%-3926.10%-518.90%-67.90%
Leverage & Solvency Ratios
Debt/Equity0.000.010.012.770.280.01
Liquidity Ratios
Current Ratio34.0054.6710.490.941.9015.05
Quick Ratio33.6854.2610.380.641.6014.46
Efficiency Ratios
Asset Turnover---0.010.010.00
Yield & Distribution Ratios
Earnings Yield-9.91%-12.35%-33.22%-293.13%-192.08%-41.59%
FCF Yield-3.62%-7.69%-29.91%-269.92%-167.86%-39.10%
Buyback Yield-28.58%-97.17%-1225.17%-188.30%-90.24%-320.63%

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Benitec Biopharma Financial Ratios

What is Benitec Biopharma's return on equity?

Benitec Biopharma's return on equity (ROE) was -33.2% for fiscal 2026 (period ended Jun 30, 2026). It was -52.5% a year earlier.

What is Benitec Biopharma's debt-to-equity ratio?

Benitec Biopharma's debt-to-equity ratio was 0.00 for fiscal 2026 (period ended Jun 30, 2026). It was 0.01 a year earlier.

What is return on equity (ROE)?

Return on equity is net income divided by shareholders' equity. It measures how much profit a company generates from the capital its shareholders have invested. Full definition